Quote this publication Share Print

ONGLYZA

-
Opinions on drugs - Posted on Jun 10 2013

Reason for request

Extension of indication

-


Actual benefit

Faible

Low, and provisional pending re-evaluation of gliptins in triple therapy, in combination with insulin and metformin when this combination alone, with diet and exercise, does not provide adequate glycaemic control.

Insuffisant

Insufficient, and provisional pending re-assessment of gliptins in dual therapy, in combination with insulin when this treatment alone, with diet and exercise, does not provide adequate glycaemic control, for reimbursement by national insurance.


Improvement in actual benefit

V (absence)

In triple therapy in combination with insulin and metformin, ONGLYZA does not offer any improvement in actual benefit (IAB V, non-existent) in the treatment of patients with type 2 diabetes in whom this combination alone, with diet and exercise, does not provide adequate glycaemic control.

Sans objet

In dual therapy in combination with insulin : not applicable.


Contact Us

Évaluation des médicaments

See also